COMMUNIQUÉS West-GlobeNewswire

UPDATE— Taconic Biosciences Becomes the First Animal Model Provider on General Services Administration Contract Schedule
20/09/2018
RENSSELAER, N.Y., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing genetically engineered rodent model solutions, announces a new relationship with Government Scientific Source (GSS [...]
VALNEVA Announces Extension of Drawdown Period for its Existing European Investment Bank Loan
20/09/2018
Valneva Announces Extension of Drawdown Period for its Existing European Investment Bank Loan Saint Herblain (France), September 20, 2018 - Valneva SE ("Valneva" or "the Company"), a commercial stage biotech company [...]
VALNEVA obtient une prolongation du prêt de la Banque Européenne d'Investissement
20/09/2018
Valneva obtient une prolongation du prêt de la Banque Européenne d'Investissement Saint-Herblain (France), 20 septembre 2018 - Valneva SE ("Valneva" ou "le Groupe"), société de biotechnologie dédiée au développement, à [...]
Issue of Shares & PDMR Announcement
20/09/2018
LONDON, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for [...]
Oxurion nv Enrolls First Patient in Phase 1 Clinical Trial Evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for Treatment of Diabetic Macular Edema (DME)
20/09/2018
Leuven, Belgium, 20 September 2018 - Oxurion NV (Euronext Brussels: OXUR - formerly known as ThromboGenics ), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diseases [...]
Taconic Biosciences Becomes the First Animal Model Provider on Federal General Services Administration
20/09/2018
RENSSELAER, N.Y., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing genetically engineered rodent model solutions, announces a new relationship with Government Scientific Source (GSS [...]
BioCorRx to Exhibit at the 2nd Annual National Opioid Crisis Management Congress
20/09/2018
ANAHEIM, CA, Sept. 20, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today [...]
Orphazyme to Present at 25th NPUK Annual Family Conference 2018
20/09/2018
Orphazyme A/S Investor news No. 11/2018 Company Registration No. 32266355 Copenhagen, September 20, 2018 – Orphazyme A/S , a biopharmaceutical company dedicated to developing treatments for patients living with rare [...]
AMAG Pharmaceuticals Partners With Emmy-Nominated Actress Cheryl Hines and Dr. Marla Shapiro to Start a Conversation About an Often Unrecognized and Untreated Medical Condition, Painful Sex Due to Menopause
20/09/2018
Campaign Seeks to Help Women Recognize this Condition and Empower Them to Talk to Their Healthcare Providers about Treatment Options WALTHAM, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: [...]
Innovation Pharmaceuticals Provides Corporate Update Highlighting Upcoming Milestones and Events
20/09/2018
BEVERLY, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to provide a corporate update on upcoming milestones and [...]
EDAP TMS SA : EDAP announces Installation of First Focal One HIFU device in South Korea
20/09/2018
Successful HIFU Treatments Performed in Seoul National University Bundang Hospital LYON, France, September 20, 2018 -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the [...]
NSS Labs Announces 2018 Next Generation Intrusion Prevention Group Test Results
20/09/2018
5 Products Receive Recommended Rating; 2 Receive Caution Rating AUSTIN, Texas, Sept. 20, 2018 (GLOBE NEWSWIRE) -- NSS Labs, Inc., a global leader and trusted source for independent, fact-based cybersecurity guidance, [...]
H1 Launches ‘Strategy as a Service’ Offering That Helps Life Sciences Companies Cut Time-to-Market in Half
20/09/2018
DaVinci service helps clients identify and unlock valuable opportunities faster NEW YORK, Sept. 20, 2018 (GLOBE NEWSWIRE) -- H1 , the first company to arm healthcare organizations with live data insights to help fight [...]
Auxly Announces Strategic Investment in FSD Pharma
20/09/2018
VANCOUVER, British Columbia, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Auxly Cannabis Group Inc. (TSX.V: XLY) (OTCQX: CBWTF) (" Auxly " or the " Company ") is pleased to announce that, as part of the strategic alliance and [...]
Teladoc Health Launches Teladoc Global Care Services
20/09/2018
Unique new offering enables multinational employers and insurers to seamlessly provide access to care for individuals while abroad PURCHASE, NY, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global [...]
North Bud Farms Closes $944,500 Private Placement
20/09/2018
TORONTO, Sept. 20, 2018 (GLOBE NEWSWIRE) -- North Bud Farms Inc . (CSE: NBUD) (the " Corporation "), is pleased to announce the closing of a non-brokered private placement offering (the " Private Placement ") consisting [...]
Portola Pharmaceuticals Names Scott Garland President and Chief Executive Officer
20/09/2018
– Relypsa president and former Exelixis chief commercial officer brings significant commercial and operational expertise – – Commercial responsibility for two of the industry’s most successful therapies, Avastin and [...]
Cancer Genetics Offers Oncomine Comprehensive Assay to Drive Clinical Trials
20/09/2018
RUTHERFORD, N.J., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today [...]
Novo Nordisk - Oral semaglutide demonstrates greater reductions in HbA1c and body weight and comparable number of adverse events vs dulaglutide in Japanese people with type 2 diabetes
20/09/2018
Bagsværd, Denmark, 20 September 2018 - Novo Nordisk today announced the headline results from PIONEER 10, a phase 3a trial with oral semaglutide vs once-weekly subcutaneous dulaglutide, both in combination with one oral [...]

Pages